53194
document
Significant differential effects of omega-3 fatty acids and fenofibrate in patients with hypertriglyceridemia . BACKGROUND Omega-3 fatty acids and fenofibrate are both used to treat patients with hypertriglyceridemia . However , a head-to-head comparison of the lipoprotein and metabolic effects of these two medicines has not been published . METHODS This was a randomized , single-blind , placebo-controlled , parallel study . Age , sex , and body mass index were matched among groups . All patients were recommended to maintain a low fat diet . Fifty patients in each group were given placebo , omega-3 fatty acids 2 g ( most commonly used dosage in Korean patients ) , or fenofibrate 160 mg , respectively daily for 2 months . RESULTS Omega-3 fatty acids therapy decreased triglycerides by 21 % and triglycerides/HDL cholesterol and improved flow-mediated dilation ( P < 0.01 ) , however , did not significantly change insulin , plasma adiponectin levels , and insulin sensitivity ( determined by QUICKI ) relative to baseline measurements . Fenofibrate therapy decreased total cholesterol , triglycerides by 29 % , and triglycerides/HDL-cholesterol ( all P < 0.01 ) and improved flow-mediated dilation when compared with baseline . When compared with placebo and omega-3 fatty acids , fenofibrate therapy decreased non-HDL cholesterol ( P < 0.001 ) and triglycerides/HDL cholesterol ( P=0.016 ) while increasing HDL cholesterol ( P < 0.001 ) and apolipoprotein AI ( P=0.001 ) . Of note , when compared with omega-3 fatty acids , fenofibrate therapy decreased fasting insulin ( P=0.023 ) and increased plasma adiponectin ( P=0.002 ) and insulin sensitivity ( P=0.015 ) . CONCLUSIONS Omega-3 fatty acids and fenofibrate therapy promoted similar changes in triglycerides and endothelium-dependent dilation . However , fenofibrate therapy had substantially better effects on lipoprotein and metabolic profiles in patients with hypertriglyceridemia .
53195
Intervention_Pharmacological
omega-3 fatty acids
53196
Intervention_Pharmacological
fenofibrate
53197
Intervention_Pharmacological
Omega-3 fatty acids
53198
Intervention_Pharmacological
fenofibrate
53199
Intervention_Control
placebo
53200
Intervention_Pharmacological
omega-3 fatty acids
53201
Intervention_Pharmacological
fenofibrate 160 mg
53202
Intervention_Physical
Omega-3 fatty acids therapy
53203
Intervention_Physical
Fenofibrate therapy
53204
Intervention_Control
placebo
53205
Intervention_Physical
omega-3 fatty acids
53206
Intervention_Physical
fenofibrate therapy
53207
Outcome_Physical
hypertriglyceridemia
53208
Outcome_Physical
triglycerides
53209
Outcome_Physical
triglycerides/HDL cholesterol
53210
Outcome_Physical
flow-mediated dilation
53211
Outcome_Physical
insulin
53212
Outcome_Physical
plasma adiponectin levels
53213
Outcome_Physical
insulin sensitivity
53214
Outcome_Physical
total cholesterol
53215
Outcome_Physical
triglycerides
53216
Outcome_Physical
triglycerides/HDL-cholesterol
53217
Outcome_Physical
improved flow-mediated dilation
53218
Outcome_Physical
non-HDL cholesterol
53219
Outcome_Physical
triglycerides/HDL cholesterol
53220
Outcome_Physical
HDL cholesterol
53221
Outcome_Physical
apolipoprotein AI
53222
Outcome_Physical
fasting insulin
53223
Outcome_Physical
plasma adiponectin
53224
Outcome_Physical
insulin sensitivity
53225
Outcome_Physical
triglycerides
53226
Outcome_Physical
endothelium-dependent dilation
53227
Outcome_Physical
lipoprotein
53228
Outcome_Physical
metabolic profiles
53229
Participant_Condition
hypertriglyceridemia
53230
Participant_Condition
hypertriglyceridemia
53231
Participant_Sample-size
Fifty
53232
Participant_Condition
hypertriglyceridemia